The sixth affiliated hospital of Sun Yat-Sen University

Guangzhou 510655

4 studies enrolling now · 13 studies all time

What they study most

Cholangiocarcinoma, Deep Venous Thrombosis, GIST, Gastric Cancer, Gastroesophageal-junction Cancer, Gastrointestinal Neoplasms, HER2-positive Gastric Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis, Monoclonal Antibody, Neoplasm Metastasis

Studies at this site

• LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis — Recruiting now
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer — Recruiting now
• EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers — Recruiting now
• A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling
• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE — Stopped early
• Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) — Stopped early
• A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE — Stopped early
• A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer — Completed
• A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis. — Completed
• (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST — Completed